{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:24:48Z","timestamp":1777983888793,"version":"3.51.4"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>Broad-spectrum antibiotics are commonly used by physicians to treat various infections. The source of infection and causative organisms are not always apparent during the initial evaluation of the patient, and antibiotics are often given empirically to patients with suspected sepsis. Fear of attempting cephalosporins and carbapenems in penicillin-allergic septic patients may result in significant decrease in the spectrum of antimicrobial coverage. Empiric antibiotic therapy should sufficiently cover all the suspected pathogens, guided by the bacteriologic susceptibilities of the medical center. It is important to understand the major pharmacokinetic properties of antibacterial agents for proper use and to minimize the development of resistance. In several septic patients, negative cultures do not exclude active infection and positive cultures may not represent the actual infection. This article will review the important differences in the spectrum of commonly used antibiotics for nosocomial bacterial infections with a particular emphasis on culture-negative sepsis and colonization.<\/jats:p>","DOI":"10.1097\/mjt.0000000000000042","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T09:46:11Z","timestamp":1389347171000},"page":"e982-e994","source":"Crossref","is-referenced-by-count":15,"title":["Empiric Antibiotic Therapy of Nosocomial Bacterial Infections"],"prefix":"10.1097","volume":"23","author":[{"given":"Pramod","family":"Reddy","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of General Internal Medicine, University of Florida, Jacksonville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/MAJ.0b013e31824ae504","article-title":"Fever of unknown origin: an evidence-based review","volume":"344","author":"Hayakawa","year":"2012","journal-title":"Am J Med Sci."},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1586\/eri.12.50","article-title":"Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes","volume":"10","author":"Martin","year":"2012","journal-title":"Expert Rev Anti Infect Ther."},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1055\/s-0030-1254046","article-title":"Disseminated intravascular coagulation in infectious disease","volume":"36","author":"Levi","year":"2010","journal-title":"Semin Thromb Hemost."},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.mayocp.2011.12.003","article-title":"Mechanisms of resistance and clinical relevance of resistance to \u03b2-lactams, glycopeptides, and fluoroquinolones","volume":"87","author":"Rice","year":"2012","journal-title":"Mayo Clin Proc."},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure of beta-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of \u03b2-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/nyas.12023","article-title":"Proliferation and significance of clinically relevant \u03b2-lactamases","volume":"1277","author":"Bush","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0002-9343(97)00044-2","article-title":"Antimicrobial resistance with focus on \u03b2-lactam resistance in gram-negative bacilli","volume":"103","author":"Pitout","year":"1997","journal-title":"Am J Med."},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fmb.11.49","article-title":"Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes","volume":"6","author":"Falagas","year":"2011","journal-title":"Future Microbiol."},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2012.06796.x","article-title":"Metallo-\u03b2-lactamase structure and function","volume":"1277","author":"Palzkill","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1099\/jmm.0.052555-0","article-title":"Global spread of antibiotic resistance: the example of New Delhi metallo-\u03b2-lactamase (NDM)-mediated carbapenem resistance","volume":"62","author":"Johnson","year":"2013","journal-title":"J Med Microbiol."},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1476-0711-11-32","article-title":"Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports","volume":"11","author":"Lee","year":"2012","journal-title":"Ann Clin Microbiol Antimicrob."},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1469-0691.2011.03734.x","article-title":"Colistin: new lessons on an old antibiotic","volume":"18","author":"Yahav","year":"2012","journal-title":"Clin Microbiol Infect."},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis."},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1749-6632.2012.06809.x","article-title":"\u03b2-Lactam antimicrobials: what have you done for me lately?","volume":"1277","author":"Talbot","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nyas.12010","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations in clinical development","volume":"1277","author":"Shlaes","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.00218-06","article-title":"Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility","volume":"50","author":"Zimhony","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/0003-4819-115-8-585","article-title":"Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy","volume":"115","author":"Chow","year":"1991","journal-title":"Ann Intern Med."},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2165\/11635660-000000000-00000","article-title":"Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections","volume":"72","author":"Lodise","year":"2012","journal-title":"Drugs"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1586\/eri.12.112","article-title":"Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA","volume":"10","author":"Garrison","year":"2012","journal-title":"Expert Rev Anti Infect Ther."},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2146\/ajhp090285","article-title":"Ceftobiprole: a novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"67","author":"Dauner","year":"2010","journal-title":"Am J Health Syst Pharm."},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.idc.2009.06.007","article-title":"Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime","volume":"23","author":"Bazan","year":"2009","journal-title":"Infect Dis Clin North Am."},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QCO.0b013e3283553441","article-title":"Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare","volume":"25","author":"Calfee","year":"2012","journal-title":"Curr Opin Infect Dis."},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.mib.2012.08.003","article-title":"Global epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA)","volume":"15","author":"Mediavilla","year":"2012","journal-title":"Curr Opin Microbiol."},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N Engl J Med."},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/499815","article-title":"Emergence of community associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections","volume":"42","author":"Seybold","year":"2006","journal-title":"Clin Infect Dis."},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3109\/00365548.2012.664779","article-title":"Community-associated methicillin-resistant Staphylococcus aureus endocarditis 'down under': case series and literature review","volume":"44","author":"Townell","year":"2012","journal-title":"Scand J Infect Dis."},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhin.2009.07.004","article-title":"Community-associated meticillin-resistant Staphylococcus aureus as a cause of hospital-acquired infections","volume":"73","author":"Skov","year":"2009","journal-title":"J Hosp Infect."},{"key":"R30-20230917","first-page":"282","article-title":"New antimicrobial agents for methicillin-resistant Staphylococcus aureus","volume":"11","author":"Kollef","year":"2009","journal-title":"Crit Care Resusc"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00281-011-0296-2","article-title":"Molecular basis of Staphylococcus epidermidis infections","volume":"34","author":"Otto","year":"2012","journal-title":"Semin Immunopathol"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10096-011-1270-6","article-title":"Coagulase-negative staphylococci: update on the molecular epidemiology and clinical presentation, with a focus on Staphylococcus epidermidis and Staphylococcus saprophyticus","volume":"31","author":"Widerstr\u00f6m","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/591861","article-title":"NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006\u20132007","volume":"29","author":"Hidron","year":"2008","journal-title":"Infect Control Hosp Epidemiol."},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/14787210.6.5.637","article-title":"Emergence and management of drug-resistant enterococcal infections","volume":"6","author":"Arias","year":"2008","journal-title":"Expert Rev Anti Infect Ther."},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4161\/viru.21282","article-title":"Intrinsic and acquired resistance mechanisms in enterococcus","volume":"3","author":"Hollenbeck","year":"2012","journal-title":"Virulence"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/14656566.2.2.293","article-title":"Linezolid\u2013a review of the first oxazolidinone","volume":"2","author":"Norrby","year":"2001","journal-title":"Expert Opin Pharmacother."},{"issue":"Suppl 4","key":"R37-20230917","first-page":"iv7","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/dkl219","article-title":"Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence","volume":"58","author":"Falagas","year":"2006","journal-title":"J Antimicrob Chemother."},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0924-8579(03)00087-6","article-title":"Activity of linezolid against anaerobic bacteria","volume":"22","author":"Behra-Miellet","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/2047-783X-15-12-507","article-title":"Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin?\u2014comparison of pharmacology and clinical efficacy","volume":"15","author":"Pletz","year":"2010","journal-title":"Eur J Med Res."},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1086\/498509","article-title":"High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease","volume":"42","author":"Wu","year":"2006","journal-title":"Clin Infect Dis."},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/1389557511209030202","article-title":"Daptomycin: a review of properties, clinical use, drug delivery and resistance","volume":"12","author":"Vilhena","year":"2012","journal-title":"Mini Rev Med Chem."},{"issue":"Suppl 1","key":"R43-20230917","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1179\/joc.2009.21.Supplement-1.36","article-title":"Tigecycline: a new treatment option for intra-abdominal infections","volume":"21","author":"Menichetti","year":"2009","journal-title":"J Chemother."},{"issue":"Suppl 2","key":"R44-20230917","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1093\/cid\/cis355","article-title":"Current state of Clostridium difficile treatment options","volume":"55","author":"Venugopal","year":"2012","journal-title":"Clin Infect Dis."},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1086\/648720","article-title":"Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials","volume":"50","author":"Gardiner","year":"2010","journal-title":"Clin Infect Dis."},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1586\/eri.12.81","article-title":"Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies","volume":"10","author":"Nannini","year":"2012","journal-title":"Expert Rev Anti Infect Ther."},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijantimicag.2012.05.014","article-title":"In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009","volume":"40","author":"Morrissey","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jac\/44.2.251","article-title":"The efficacy and safety of quinupristin\/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group","volume":"44","author":"Moellering","year":"1999","journal-title":"J Antimicrob Chemother."},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0002-9343(03)00420-0","article-title":"Clostridium difficile infection in patients with unexplained leukocytosis","volume":"115","author":"Wanahita","year":"2003","journal-title":"Am J Med."},{"key":"R50-20230917","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ajg.2013.4","article-title":"Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections","volume":"108","author":"Surawicz","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"R51-20230917","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/QCO.0b013e328363456e","article-title":"New developments in chemotherapeutic options for Clostridium difficile colitis","volume":"26","author":"Ritter","year":"2013","journal-title":"Curr Opin Infect Dis."},{"key":"R52-20230917","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.mcna.2006.07.005","article-title":"Antibiotic selection in the penicillin-allergic patient","volume":"90","author":"Cunha","year":"2006","journal-title":"Med Clin North Am."},{"key":"R53-20230917","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/0003-4819-146-4-200702200-00005","article-title":"Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins","volume":"146","author":"Romano","year":"2007","journal-title":"Ann Intern Med."},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2500\/aap.2012.33.3526","article-title":"Physician approaches to beta-lactam use in patients with penicillin hypersensitivity","volume":"33","author":"Prematta","year":"2012","journal-title":"Allergy Asthma Proc."},{"key":"R55-20230917","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jaci.2010.06.052","article-title":"IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems","volume":"126","author":"Romano","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"R56-20230917","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1179\/joc.2008.20.2.233","article-title":"Safety of meropenem in patients reporting penicillin allergy: lack of allergic cross reactions","volume":"20","author":"Cunha","year":"2008","journal-title":"J Chemother."},{"key":"R57-20230917","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med."},{"key":"R58-20230917","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00134-012-2808-5","article-title":"Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors","volume":"39","author":"Martin-Loeches","year":"2013","journal-title":"Intensive Care Med."},{"key":"R59-20230917","first-page":"471","article-title":"Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia","volume":"39","author":"El Solh","year":"2004","journal-title":"Clin Infect Dis."},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/ers.12.45","article-title":"Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens","volume":"6","author":"Grgurich","year":"2012","journal-title":"Expert Rev Respir Med."},{"key":"R61-20230917","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis."},{"key":"R62-20230917","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/QCO.0b013e32835023fb","article-title":"Is healthcare-associated pneumonia a distinct entity needing specific therapy?","volume":"25","author":"Ewig","year":"2012","journal-title":"Curr Opin Infect Dis."},{"key":"R63-20230917","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1473-3099(10)70032-3","article-title":"Rethinking the concepts of community-acquired and health-care-associated pneumonia","volume":"10","author":"Ewig","year":"2010","journal-title":"Lancet Infect Dis."},{"key":"R64-20230917","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/QCO.0b013e328329fa4e","article-title":"Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia","volume":"22","author":"Brito","year":"2009","journal-title":"Curr Opin Infect Dis."},{"key":"R65-20230917","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1378\/chest.09-1652","article-title":"A comparison of culture-positive and culture-negative healthcare-associated pneumonia","volume":"137","author":"Labelle","year":"2010","journal-title":"Chest"},{"key":"R66-20230917","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s15010-010-0042-z","article-title":"Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia","volume":"38","author":"Schlueter","year":"2010","journal-title":"Infection"},{"key":"R67-20230917","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1473-3099(12)70323-7","article-title":"Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis","volume":"13","author":"Wacker","year":"2013","journal-title":"Lancet Infect Dis."},{"key":"R68-20230917","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/CCM.0b013e3181eb3ccd","article-title":"Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis","volume":"38","year":"2010","journal-title":"Crit Care Med."},{"key":"R69-20230917","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.2013.278477","article-title":"Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial","volume":"310","author":"Morelli","year":"2013","journal-title":"JAMA"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00045391-201607000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T00:02:01Z","timestamp":1694908921000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201607000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0000000000000042","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1038\/s41598-026-46118-4","asserted-by":"object"}]},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}